Cargando…
Epithelial-Mesenchymal Transition and MicroRNAs in Colorectal Cancer Chemoresistance to FOLFOX
The FOLFOX scheme, based on the association of 5-fluorouracil and oxaliplatin, is the most frequently indicated chemotherapy scheme for patients diagnosed with metastatic colorectal cancer. Nevertheless, development of chemoresistance is one of the major challenges associated with this disease. It h...
Autores principales: | Escalante, Paula I., Quiñones, Luis A., Contreras, Héctor R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827270/ https://www.ncbi.nlm.nih.gov/pubmed/33429840 http://dx.doi.org/10.3390/pharmaceutics13010075 |
Ejemplares similares
-
Epithelial-Mesenchymal Transition-Related MicroRNAs and Their Target Genes in Colorectal Cancerogenesis
por: Ranković, Branislava, et al.
Publicado: (2019) -
MicroRNAs and epithelial-mesenchymal transition in prostate cancer
por: Sekhon, Kirandeep, et al.
Publicado: (2016) -
Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer
por: Legras, Antoine, et al.
Publicado: (2017) -
MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX
por: Kiss, I., et al.
Publicado: (2017) -
MicroRNAs: regulators of cancer metastasis and epithelial-mesenchymal transition (EMT)
por: Ding, Xiang-Ming
Publicado: (2014)